ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: IMGN
- CUSIP: 45253H10
- Previous Close: $2.43
- 50 Day Moving Average: $2.42
- 200 Day Moving Average: $2.38
- 52-Week Range: $1.51 - $9.78
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.68
- P/E Growth: 0.00
- Market Cap: $212.79M
- Outstanding Shares: 87,301,000
- Beta: 1.98
- Net Margins: -292.83%
- Return on Assets: -60.67%
Companies Related to ImmunoGen:
- Debt-to-Equity Ratio: -0.79%
- Current Ratio: 3.69%
- Quick Ratio: 3.65%
What is ImmunoGen's stock symbol?
ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."
Where is ImmunoGen's stock going? Where will ImmunoGen's stock price be in 2017?
9 analysts have issued 1-year price objectives for ImmunoGen's shares. Their predictions range from $3.00 to $11.00. On average, they anticipate ImmunoGen's share price to reach $6.28 in the next twelve months.
When will ImmunoGen announce their earnings?
ImmunoGen is scheduled to release their next quarterly earnings announcement on Thursday, April, 27th 2017.
Who owns ImmunoGen stock?
ImmunoGen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include
PRIMECAP MANAGEMENT COMPANY
(7.57%), Orbimed Advisors LLC (6.98%), Renaissance Technologies LLC (2.84%), Pinnacle Associates Ltd. (1.86%), State Street Corp (1.75%) and FMR LLC (0.92%). Company insiders that own ImmunoGen stock include Charles Q Morris, Craig Barrows, Daniel M Junius, David Brannon Johnston, Dean J Mitchell, John Lambert, Mark Alan Goldberg, Mark J Enyedy, Nicole Onetto and Richard J Gregory.
Who sold ImmunoGen stock? Who is selling ImmunoGen stock?
ImmunoGen's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Pinnacle Associates Ltd., AQR Capital Management LLC, Renaissance Technologies LLC and Two Sigma Investments LP.
Who bought ImmunoGen stock? Who is buying ImmunoGen stock?
ImmunoGen's stock was acquired by a variety of institutional investors in the last quarter, including Moloney Securities Asset Management LLC, State Street Corp and Federated Investors Inc. PA. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Dean J Mitchell, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory.
How do I buy ImmunoGen stock?
Shares of ImmunoGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of ImmunoGen stock cost?
One share of ImmunoGen stock can currently be purchased for approximately $2.43.